Search Within

Hong Shao

  1. "Epidemiology and Biostatistics"
Formats
  1. Meeting Abstract (4)
  2. Journal Article (1)
Groups
  1. Breast Medicine Service (5)
  2. Center for Molecular Imaging and Biotechnology (CMIB) (5)
  3. Computational Oncology Service (5)
  4. Department of Medicine (5)
  5. Epidemiology and Biostatistics (5)
  6. GSK Faculty (5)

More Groups

People
  1. Eduard Reznik (5)
  2. Maurizio Scaltriti (5)
  3. Neil Vasan (5)
  4. Pedram Razavi (5)
  5. Abiha Kazmi (4)
  6. Alexander Gorelick (4)

More People

Years
  1. 2020 (2)
  2. 2019 (3)
Publications
  1. Cancer Research (2)
  2. Annals of Oncology (1)
  3. Molecular Cancer Research (1)
  4. Science (1)
Publishers
  1. American Association for Cancer Research (3)
  2. American Association for the Advancement of Science (1)
  3. Oxford University Press (1)

Results (5)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors
    Meeting Abstract

    Vasan, N.; Razavi, P.; Johnson, J. L.; Shao, H.; Shah, H.; Antoine, A.; Ladewig, E.; Gorelick, A.; Lin, T. Y.; Toska, E.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Compound PIK3CA mutations support a mutational dose-response model for oncogene activation and response to PI3K inhibitor targeted therapy in breast cancer
    Meeting Abstract

    Vasan, N.; Johnson, J.; Shao, H.; Razavi, P.; Gorelick, A.; Ladewig, E.; Antoine, A.; Shah, H.; Toska, E.; Xu, G.; more...
    Molecular Cancer Research (2020)

    Fulltext@MSK | Save
  • Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Ka inhibitors
    Journal Article

    Vasan, N.; Razavi, P.; Johnson, J. L.; Shao, H.; Shah, H.; Antoine, A.; Ladewig, E.; Gorelick, A.; Lin, T. Y.; Toska, E.; more...
    Science (2019)

    Fulltext@MSK | Save
  • Double PIK3CA mutations in cis enhance oncogene activation and sensitivity to PI3K alpha inhibitors in breast cancer
    Meeting Abstract

    Vasan, N.; Razavi, P.; Johnson, J.; Shao, H.; Shah, H.; Antoine, A.; Ladewig, E.; Gorelick, A.; Toska, E.; Xu, G.; more...
    Cancer Research (2019)

    Fulltext@MSK | Save
  • Double PIK3CA mutations in cis enhance PI3Kα oncogene activation and sensitivity to PI3Kα inhibitors in breast cancer
    Meeting Abstract

    Vasan, N.; Razavi, P.; Johnson, J. L.; Shao, H.; Reznik, E.; Smith, M. L.; Sebra, R.; Cantley, L. C.; Scaltriti, M.; Baselga, J.
    Annals of Oncology (2019)

    Fulltext@MSK | Save